Haynes and Boone Advises Kitov Pharmaceuticals Holdings in $13 Million Nasdaq Initial Public Offering

11/24/2015

Haynes and Boone, LLP has advised Kitov Pharmaceuticals Holdings Ltd. in its $13 million initial public offering and Nasdaq listing.

New York Partner Rick Werner and Associate Robert Little led the Haynes and Boone team in the transaction, which was underwritten by Rodman & Renshaw, a unit of H.C. Wainwright & Co., and Joseph Gunnar & Co., LLC.

Kitov, an Israeli-based biopharmaceutical company listed on the Tel Aviv Stock Exchange, is focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions

The company plans to use the net proceeds from the offering to fund its ongoing development plan, for the repayment of indebtedness and for working capital and other general corporate purposes.

Kitov opened trading on the Nasdaq Capital Market Nov. 20 under the symbols "KTOV" and "KTOVW.” The offering is expected to close on or about Nov. 25 subject to customary closing conditions.


About Kitov Pharmaceuticals Holdings Ltd.

Kitov Pharmaceuticals Holdings Ltd. is a biopharmaceutical company focused on the development of therapeutic candidates for the simultaneous treatment of various clinical conditions. In particular, Kitov focuses on developing combinations of existing drugs in advanced stages of development.

Media Contacts

Nathan Koppel
Director of Media Relations
+1 512.867.8431
nathan.koppel@haynesboone.com
Linda Campbell
Communications Manager
+1 214.651.5362
linda.campbell@haynesboone.com

Email Disclaimer